Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)_Chinese Journal of Evidence-Based Medicine

Authors：

LI Liushui , CHEN Jing , LIU Yang ,  LIU Xianjun

Beijing Luhe Hospital, Capital Medical University, Beijing 101149, P. R. China;

Corresponding author：

LIU Xianjun, Email: xjxianjun@163.com

Keywords：

Drug evaluation; Drug selection; Multi-dimensional quantitative evaluation; Rapid-acting insulin analogue; Insulin aspart; Insulin lispro; Insulin glulisine

DOI：

10.7507/1672-2531.202403100

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective This study aims to conduct a multi-dimensional quantitative evaluation of three rapid-acting insulin analogues, aspart (Novolog), lispro (Humalog), and glulisine (Apidra) to provide references for the selection of these drugs in medical institutions. Methods The recommended methods from the "Quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)" were employed to evaluate the pharmaceutical characteristics, effectiveness, safety, cost-effectiveness, and other attributes of the three rapid-acting insulin analogues. Results The total scores of insulins aspart (Novolog), lispro (Humalog), and glulisine (Apidra) were 73.5, 80.4, and 70.9, respectively. Insulin lispro (Humalog) had the highest score, demonstrating a prominent advantage in both effectiveness and cost-effectiveness dimensions. Conversely, insulin glulisine (Apidra) had the lowest score, with ratings in effectiveness and safety dimensions lower than those of the other two rapid-acting insulin analogs. Conclusion When selecting rapid-acting insulin analogs, healthcare institutions can choose one or more insulins, aspart (Novolog), lispro (Humalog), or glulisine (Apidra), all of which are strongly recommended, with priority given to insulin lispro (Humalog), which has the highest total score.

Citation： LI Liushui, CHEN Jing, LIU Yang, LIU Xianjun. Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition). Chinese Journal of Evidence-Based Medicine, 2024, 24(10): 1141-1148. doi: 10.7507/1672-2531.202403100 Copy

1.	赵志刚, 董占军, 刘建平. 中国医疗机构药品评价与遴选快速指南(第二版). 医药导报, 2023, 42(4): 447-456.
2.	美国卫生及公共服务部. 常见不良事件评价标准(CTCAE) 5.0版.
3.	国家医保局, 人力资源社会保障部. 关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2023年)》的通知.
4.	国家卫生健康委员会. 国家基本药物目录-2018年版.
5.	中国医药统计网. 2022年度中国医药工业百强企业榜单.
6.	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版). 中华糖尿病杂志, 2021, 13(4): 315-409.
7.	国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2024版). 中华糖尿病杂志, 2024, 16(2): 147-189.
8.	中华医学会糖尿病学分会, 国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理指南(2022). 中华内科杂志, 2022, 61(3): 249-262.
9.	中华医学会内分泌学分会, 中华医学会糖尿病学分会, 中国医师协会内分泌代谢科医师分会. 中国胰岛素泵治疗指南(2021年版). 中华内分泌代谢杂志, 2021, 37(8): 679-701.
10.	中华医学会糖尿病学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会内分泌学分会, 等. 中国1型糖尿病诊治指南(2021版). 中华糖尿病杂志, 2022, 14(11): 1143-1250.
11.	中华医学会, 中华医学会临床药学分会, 中华医学会杂志社, 等. 2型糖尿病基层合理用药指南. 中华全科医师杂志, 2021, 20(6): 615-630.
12.	中华医学会, 《中华全科医师杂志》编辑委员会, 《基层2型糖尿病胰岛素应用专家共识》编写专家组. 基层2型糖尿病胰岛素应用专家共识. 中华全科医师杂志, 2021, 20(7): 726-736.
13.	American Diabetes Association Professional Practice Committee. Erratum. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care, 2024, 47(Suppl.1): S158-S178.
14.	Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract, 2022, 28(10): 923-1049.
15.	Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021, 27(6): 505-537.
16.	贾伟平, 包玉倩, 缪珩, 等. 两种门冬胰岛素治疗糖尿病的有效性及安全性比较: 多中心、随机、开放、对照试验. 中华内科杂志, 2021, 60(12): 1148-1156.
17.	金仙, 张金苹, 边芳, 等. 重组赖脯胰岛素治疗糖尿病的疗效及安全性: 多中心、随机、阳性药物平行对照临床试验. 中华糖尿病杂志, 2020, 12(12): 974-980.
18.	Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract, 2007, 76(2): 304-312.

1. 赵志刚, 董占军, 刘建平. 中国医疗机构药品评价与遴选快速指南(第二版). 医药导报, 2023, 42(4): 447-456.
2. 美国卫生及公共服务部. 常见不良事件评价标准(CTCAE) 5.0版.
3. 国家医保局, 人力资源社会保障部. 关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2023年)》的通知.
4. 国家卫生健康委员会. 国家基本药物目录-2018年版.
5. 中国医药统计网. 2022年度中国医药工业百强企业榜单.
6. 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版). 中华糖尿病杂志, 2021, 13(4): 315-409.
7. 国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2024版). 中华糖尿病杂志, 2024, 16(2): 147-189.
8. 中华医学会糖尿病学分会, 国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理指南(2022). 中华内科杂志, 2022, 61(3): 249-262.
9. 中华医学会内分泌学分会, 中华医学会糖尿病学分会, 中国医师协会内分泌代谢科医师分会. 中国胰岛素泵治疗指南(2021年版). 中华内分泌代谢杂志, 2021, 37(8): 679-701.
10. 中华医学会糖尿病学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会内分泌学分会, 等. 中国1型糖尿病诊治指南(2021版). 中华糖尿病杂志, 2022, 14(11): 1143-1250.
11. 中华医学会, 中华医学会临床药学分会, 中华医学会杂志社, 等. 2型糖尿病基层合理用药指南. 中华全科医师杂志, 2021, 20(6): 615-630.
12. 中华医学会, 《中华全科医师杂志》编辑委员会, 《基层2型糖尿病胰岛素应用专家共识》编写专家组. 基层2型糖尿病胰岛素应用专家共识. 中华全科医师杂志, 2021, 20(7): 726-736.
13. American Diabetes Association Professional Practice Committee. Erratum. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care, 2024, 47(Suppl.1): S158-S178.
14. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract, 2022, 28(10): 923-1049.
15. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021, 27(6): 505-537.
16. 贾伟平, 包玉倩, 缪珩, 等. 两种门冬胰岛素治疗糖尿病的有效性及安全性比较: 多中心、随机、开放、对照试验. 中华内科杂志, 2021, 60(12): 1148-1156.
17. 金仙, 张金苹, 边芳, 等. 重组赖脯胰岛素治疗糖尿病的疗效及安全性: 多中心、随机、阳性药物平行对照临床试验. 中华糖尿病杂志, 2020, 12(12): 974-980.
18. Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Res Clin Pract, 2007, 76(2): 304-312.

Chinese Journal of Evidence-Based Medicine

Multi-dimensional quantitative evaluation of rapid-acting insulin analogues based on the quick guideline for drug evaluation and selection in Chinese medical institutions (the second edition)

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content